FDA receives BLA for tralokinumab treatment for moderate-to-severe adhesitis
-
Last Update: 2020-07-16
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!-----specific dermatitis (AD) is a chronic, itchy, inflammatory skin disease that most commonly affects children but also affects many adultsClinical features of-specific dermatitis include dry skin, erythema, oozing and cosking, as well as moss-like changesitching is a sign of the disease and a major cause of the burden on patients and their familiesLeo Pharma, a pharmaceutical company that specializes in dermatology at the, announced today that The Biological Biologics License Application (BLA) for Tralokinumab's Treatment of Moderate to Severe Appelitis has been approved by the FDATralokinumab is an all-human monoclonal antibody that neutralizes interleukal interleukin 13 (IL-13), which is a key driver of atopic dermatitisKey Phase III clinical trials (ECZTRA 1, 2, 3 studies) have proven the safety and efficacy of tralokinumab"For patients with uncontrollable moderate to severe adhesionderitis, medical needs remain unmet," said DrKim Kj?lle, vice president of leo Pharma,If Tralokinumab is approved, Tralokinumab may become the first biological agent that can neutralize IL-13."the European Medicines Agency (EMA) recently accepted a sales license application (MAA) for tralokinumab and the Human Drug Commission (CHMP) is conducting a regulatory review
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
